Drugs / Autologous Bone Marrow Mononuclear Cell Transfusion
Autologous Bone Marrow Mononuclear Cell Transfusion
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00908856 Comparator | Jan 2016 → Dec 2017 | stroke disorder | University of California, Irvine | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06629324 Comparator | Oct 2024 → Oct 2026 expected | autism spectrum disorder | Vinmec Research Institute of Stem Cell and Gene Technology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Bone Marrow Mononuclear Cell Transfusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06629324 ↗ |
| Modality | Cell therapy | “autologous BM MNC transplantation” NCT06629324 ↗ |
| Route | Intravenous | “a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset” NCT00908856 ↗ |